Tetsu Maruyama is Chief Scientific Officer for the DDF.
After a 15-year academic career with faculty positions at the University of Minnesota in the US and Cardiff University in the UK, Tetsu moved to industry, first at Merck Sharpe and Dohme’s Neuroscience Research Centre in the UK and then at GSK, where he was the Director of the GSK Centre for Cognitive and Neurodegenerative Disorders in Singapore. In 2006 he moved to Takeda Pharmaceutical Company in Japan, first as Head of CNS Research and then as Head of Global Drug Discovery, a position he held until his appointment to DDF.
Tetsu’s background is in neuroscience, having received his PhD from Stanford University and conducted post-doctoral research at Yale University.
Outside of SV
Dementia Discovery Fund